The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Tomasz M. Beer

Knight Cancer Institute

Oregon Health & Science University

Mail code CH14R

3303 SW Bond Avenue

USA

[email]@ohsu.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Knight Cancer Institute, Oregon Health & Science University, Mail code CH14R, 3303 SW Bond Avenue, USA. 2010 - 2012
  • Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA. 2008 - 2011
  • Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon 97239, USA. 2001 - 2010

References

  1. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Beer, T.M., Smith, D.C., Hussain, A., Alonso, M., Wang, J., Giurescu, M., Roth, K., Wang, Y. Br. J. Cancer (2012) [Pubmed]
  2. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Beer, T.M., Bernstein, G.T., Corman, J.M., Glode, L.M., Hall, S.J., Poll, W.L., Schellhammer, P.F., Jones, L.A., Xu, Y., Kylstra, J.W., Frohlich, M.W. Clin. Cancer Res. (2011) [Pubmed]
  3. Acupuncture for hot flashes in patients with prostate cancer. Beer, T.M., Benavides, M., Emmons, S.L., Hayes, M., Liu, G., Garzotto, M., Donovan, D., Katovic, N., Reeder, C., Eilers, K. Urology (2010) [Pubmed]
  4. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Beer, T.M., Ryan, C., Alumkal, J., Ryan, C.W., Sun, J., Eilers, K.M. Anticancer. Drugs (2010) [Pubmed]
  5. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Beer, T.M., Goldman, B., Synold, T.W., Ryan, C.W., Vasist, L.S., Van Veldhuizen, P.J., Dakhil, S.R., Lara, P.N., Drelichman, A., Hussain, M.H., Crawford, E.D. Clin. Genitourin. Cancer (2008) [Pubmed]
  6. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Beer, T.M., Ryan, C.W., Venner, P.M., Petrylak, D.P., Chatta, G.S., Ruether, J.D., Chi, K.N., Young, J., Henner, W.D. Cancer (2008) [Pubmed]
  7. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Beer, T.M., Goldman, B., Nichols, C.R., Petrylak, D.P., Agarwal, M., Ryan, C.W., Crawford, E.D. Clin. Genitourin. Cancer (2008) [Pubmed]
  8. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Beer, T.M., Lalani, A.S., Lee, S., Mori, M., Eilers, K.M., Curd, J.G., Henner, W.D., Ryan, C.W., Venner, P., Ruether, J.D., Chi, K.N. Cancer (2008) [Pubmed]
  9. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Beer, T.M., Javle, M.M., Ryan, C.W., Garzotto, M., Lam, G.N., Wong, A., Henner, W.D., Johnson, C.S., Trump, D.L. Cancer Chemother. Pharmacol. (2007) [Pubmed]
  10. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Beer, T.M., Higano, C.S., Saleh, M., Dreicer, R., Hudes, G., Picus, J., Rarick, M., Fehrenbacher, L., Hannah, A.L. Invest. New. Drugs (2007) [Pubmed]
  11. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. Beer, T.M., Ryan, C.W., Venner, P.M., Petrylak, D.P., Chatta, G.S., Ruether, J.D., Redfern, C.H., Fehrenbacher, L., Saleh, M.N., Waterhouse, D.M., Carducci, M.A., Vicario, D., Dreicer, R., Higano, C.S., Ahmann, F.R., Chi, K.N., Henner, W.D., Arroyo, A., Clow, F.W. J. Clin. Oncol. (2007) [Pubmed]
  12. Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer. Beer, T.M., Bergenstock, M., Birt, K., Higano, C.S. Clinical. Genitourinary. Cancer (2007) [Pubmed]
  13. Testosterone loss and estradiol administration modify memory in men. Beer, T.M., Bland, L.B., Bussiere, J.R., Neiss, M.B., Wersinger, E.M., Garzotto, M., Ryan, C.W., Janowsky, J.S. J. Urol. (2006) [Pubmed]
  14. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Beer, T.M., Garzotto, M., Park, B., Mori, M., Myrthue, A., Janeba, N., Sauer, D., Eilers, K. Clin. Cancer Res. (2006) [Pubmed]
  15. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Beer, T.M., Tangen, C.M., Nichols, C.R., Margolin, K.A., Dreicer, R., Stephenson, W.T., Quinn, D.I., Raghavan, D., Crawford, E.D. Cancer (2006) [Pubmed]
  16. Calcitriol in the treatment of prostate cancer. Beer, T.M., Myrthue, A. Anticancer Res. (2006) [Pubmed]
  17. High dose calcitriol may reduce thrombosis in cancer patients. Beer, T.M., Venner, P.M., Ryan, C.W., Petrylak, D.P., Chatta, G., Dean Ruether, J., Chi, K.N., Curd, J.G., DeLoughery, T.G. Br. J. Haematol. (2006) [Pubmed]
  18. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Beer, T.M., Ryan, C., Bhat, G., Garnick, M. Anticancer. Drugs (2006) [Pubmed]
  19. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. Beer, T.M., Myrthue, A., Eilers, K.M. World. J. Urol (2005) [Pubmed]
  20. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. Beer, T.M. BJU Int. (2005) [Pubmed]
  21. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Beer, T.M., Javle, M., Lam, G.N., Henner, W.D., Wong, A., Trump, D.L. Clin. Cancer Res. (2005) [Pubmed]
  22. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Beer, T.M., Eilers, K.M., Garzotto, M., Hsieh, Y.C., Mori, M. Cancer (2004) [Pubmed]
  23. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Beer, T.M., Garzotto, M., Lowe, B.A., Ellis, W.J., Montalto, M.A., Lange, P.H., Higano, C.S. Clin. Cancer Res. (2004) [Pubmed]
  24. Calcitriol in cancer treatment: from the lab to the clinic. Beer, T.M., Myrthue, A. Mol. Cancer Ther. (2004) [Pubmed]
  25. Prevention and management of prostate cancer chemotherapy complications. Beer, T.M., Bubalo, J.S. Urol. Clin. North Am. (2004) [Pubmed]
  26. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Beer, T.M., Garzotto, M., Henner, W.D., Eilers, K.M., Wersinger, E.M. Br. J. Cancer (2004) [Pubmed]
  27. Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. Beer, T.M., Tangen, C.M., Bland, L.B., Thompson, I.M., Crawford, E.D. J. Urol. (2004) [Pubmed]
  28. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Beer, T.M., Garzotto, M., Katovic, N.M. Am. J. Clin. Oncol. (2004) [Pubmed]
  29. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy. Beer, T.M., Myrthue, A., Garzotto, M., O'hara, M.F., Chin, R., Lowe, B.A., Montalto, M.A., Corless, C.L., Henner, W.D. Cancer Epidemiol. Biomarkers Prev. (2004) [Pubmed]
  30. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Beer, T.M., Eilers, K.M., Garzotto, M., Egorin, M.J., Lowe, B.A., Henner, W.D. J. Clin. Oncol. (2003) [Pubmed]
  31. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Beer, T.M., Lemmon, D., Lowe, B.A., Henner, W.D. Cancer (2003) [Pubmed]
  32. Docetaxel (taxotere) in the treatment of prostate cancer. Beer, T.M., El-Geneidi, M., Eilers, K.M. Expert. Rev. Anticancer. Ther (2003) [Pubmed]
  33. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Beer, T.M., Garzotto, M., Henner, W.D., Eilers, K.M., Wersinger, E.M. Br. J. Cancer (2003) [Pubmed]
  34. Development of weekly high-dose calcitriol based therapy for prostate cancer. Beer, T.M. Urol. Oncol. (2003) [Pubmed]
  35. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Beer, T.M., Berry, W., Wersinger, E.M., Bland, L.B. Clin. Prostate. Cancer (2003) [Pubmed]
  36. Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer. Beer, T.M., Bubalo, J.S. Curr. Urol. Rep (2002) [Pubmed]
  37. Polymorphisms of GSTP1 and related genes and prostate cancer risk. Beer, T.M., Evans, A.J., Hough, K.M., Lowe, B.A., McWilliams, J.E., Henner, W.D. Prostate Cancer Prostatic Dis. (2002) [Pubmed]
  38. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Beer, T.M., Munar, M., Henner, W.D. Cancer (2001) [Pubmed]
  39. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Beer, T.M., Pierce, W.C., Lowe, B.A., Henner, W.D. Ann. Oncol. (2001) [Pubmed]
 
WikiGenes - Universities